<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867604</url>
  </required_header>
  <id_info>
    <org_study_id>N201811013</org_study_id>
    <nct_id>NCT03867604</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Fascial Release Injection for Myofascial Pain Syndrome in the Upper Trapezius Muscle</brief_title>
  <official_title>Ultrasound-guided Fascial Release Injection for Myofascial Pain Syndrome in the Upper Trapezius Muscle: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University WanFang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University WanFang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with myofascial pain syndrome at upper trapezius will be randomized into 2 groups,&#xD;
      fascial injection group and subcutaneous control injection group. Pain condition pain, range&#xD;
      of motion and function will be evaluated in 1 week, 4 weeks and 12 weeks after injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myofascial pain syndrome(MPS) is characterized by a trigger point with a hyperirritable&#xD;
      nodule and taut band of muscle or fascia. MPS was usually treated by dry needling or met&#xD;
      needing, local anesthetics injection, to the trigger point. According to recent researches,&#xD;
      dry and wet needling to affected muscle are effectiveness for short term and medium term pain&#xD;
      relief. Although some researches indicated an increased viscosity at fascial layer in MPS and&#xD;
      there are few studies of manipulation for fascial release. There is not study of injective&#xD;
      fascial release.&#xD;
&#xD;
      Investigators will include 40 patients with myofascial pain syndrome at upper trapezius.&#xD;
      Participants will be randomized into 2 groups, fascia injection group and subcutaneous&#xD;
      control injection group. Investigators will use algometer to measure pain threshold and peak&#xD;
      pressure, measure the range of motion of neck and shoulder and assess the neck and shoulder&#xD;
      function by questionnaire. The examination will be done before injection, immediately after&#xD;
      injection, 1 week, 4 weeks and 12 weeks after injection.&#xD;
&#xD;
      To our hypothesis, investigators suggest focal anesthetics injection could decrease the&#xD;
      fascial viscosity and improved pain and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">March 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Upper back or shoulder pain</measure>
    <time_frame>Change from baseline VAS at 1 week</time_frame>
    <description>visual analogue scale(VAS), range 0-10, the higher the worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper back or shoulder pain</measure>
    <time_frame>Change from baseline VAS at 4 week</time_frame>
    <description>visual analogue scale(VAS), range 0-10, the higher the worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper back or shoulder pain</measure>
    <time_frame>Change from baseline VAS at 12 week</time_frame>
    <description>visual analogue scale(VAS), range 0-10, the higher the worse pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>Change from baseline SPADI at 1 week</time_frame>
    <description>Shoulder Pain and Disability Index (SPADI), range 0-130, the higher the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>Change from baseline SPADI at 4 week</time_frame>
    <description>Shoulder Pain and Disability Index (SPADI), range 0-130, the higher the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>Change from baseline SPADI at 12 week</time_frame>
    <description>Shoulder Pain and Disability Index (SPADI), range 0-130, the higher the worse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Myofascial Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Sham injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subcutaneous injection at upper trapezium muscle level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fascia injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fascia injection, below upper trapezium muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Injection to the subcutaneous layer at upper trapezium level</description>
    <arm_group_label>Sham injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fascia injection</intervention_name>
    <description>Injection to the fascia below upper trapezium muscle</description>
    <arm_group_label>Fascia injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20-70 years old&#xD;
&#xD;
          -  diagnosed as a myofascial pain syndrome at upper trapezium muscle&#xD;
&#xD;
          -  trigger point&#xD;
&#xD;
          -  taut band&#xD;
&#xD;
          -  refer pain while taut band irritation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitive impairment.&#xD;
&#xD;
          -  Post operation at neck and shoulder.&#xD;
&#xD;
          -  Nerve compression at cervical region.&#xD;
&#xD;
          -  Could not receive injection therapy, history of fainting during needling&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Hsuan Cheng, Cheng</last_name>
    <role>Study Director</role>
    <affiliation>Taipei Medical University, Taiwan, R.O.C.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Hsuan Cheng, MS</last_name>
    <phone>+886 229307930</phone>
    <phone_ext>1600</phone_ext>
    <email>heathcyh@gmail.com</email>
  </overall_contact>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

